Core Insights - BetterLife Pharma Inc. is focused on developing and commercializing innovative treatments for mental disorders, specifically through its compounds BETR-001 and BETR-002 [1][9] - BETR-001, a non-hallucinogenic derivative of LSD, is currently in preclinical and IND-enabling studies, with a pending patent for its composition and method of use targeting major depressive disorder, anxiety disorder, and neuropathic pain [5][9] - The company is collaborating with researchers from Carleton University to present findings on BETR-001 at the FENS conference, highlighting its potential therapeutic effects on neuroplasticity and neurotransmission [1][8] Company Overview - BetterLife Pharma is an emerging biotechnology company primarily focused on neuro-psychiatric and neurological disorders [9] - The company also has a drug candidate aimed at treating viral infections and is exploring strategic alternatives for its further development [10] Research and Development - BETR-002 is based on honokiol, an active ingredient from magnolia bark, and is in preclinical studies targeting anxiety-related disorders, including benzodiazepine dependency [3] - Recent preclinical findings indicate that BETR-001 activates key signaling pathways related to depressive disorders and may also be effective in treating neurodegeneration and addiction disorders [5][8]
BetterLife To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria